Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Cell-Free DNA in Hematologic Malignancies.

Cell-Free DNA in Hematologic Malignancies. JCO oncology practice Schroers-Martin, J. G., Alizadeh, A. A. 2024; 20 (11): 1491-1499

Abstract

Liquid biopsy techniques using cell-free DNA (cfDNA) play an increasingly important role in the characterization and surveillance of solid tumors. For blood cancers, molecular response assessment techniques using circulating malignant cells or bone marrow aspirates are well established in clinical care. However, cfDNA has an emerging role in hematology as well, with the opportunity for disease assessment and quantification independent of circulating disease burden or invasive biopsies. In this review, we discuss key technologies and clinical data for the utilization of cfDNA in lymphomas, myeloma, and leukemias.

View details for DOI 10.1200/OP-24-00648

View details for PubMedID 39531844